Gut Permeability, Sensitivity and Symptomatology

Overview

About this study

To better understand the relationship between gut barrier function and the symptomatology and pathophysiology of IBS.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • No abdominal surgery (except appendectomy, cholecystectomy, hernia repair, hysterectomy, and C-section).
  • Written informed consent.
  • Patient is healthy control, IBS-C, or IBS-D confirmed by Rome III criteria.

Exclusion Criteria

  • Females who are pregnant or breastfeeding.
  • Use of tobacco products within the past 6 months (since nicotine may affect intestinal permeability).
  • Use of NSAIDs or aspirin within the past week (since NSAIDs affect intestinal permeability).
  • Use of oral corticosteroids within the previous 6 weeks.
  • Ingestion of artificial sweeteners such as Splenda TM (sucralose), Nutrasweet TM (aspartame), lactulose or mannitol 2 days before the study tests begins; e.g., foods to be avoided are sugarless gyms or mints and diet soda.
  • Ingestion of any prescription, over the counter, or herbal medications which can affect gastrointestinal transit 7 days before the study begins.
  • Proton pump inhibitors.
  • Antibiotics for the preceding 60 days before the start of the study.
  • Alcohol intake beyond the recommended safe limit (<21 units per week).
  • Bleeding disorders or medications that increase risk of bleeding from mucosal biopsies.
  • Known allergy to fluorescein.
  • Inflammatory bowel diseases, celiac disease.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Madhusudan Grover, M.B.B.S.

Closed for enrollment

Rochester, Minn.

Mayo Clinic principal investigator

Madhusudan Grover, M.B.B.S.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions